Medical and Health Industry Weekly Report | "Elekta" further strengthens its localized layout in China; "Leman Biotech" secures over 100 million yuan in Series A financing.
In recent years, the healthcare industry has witnessed a continuous emergence of innovations and has developed into one of the most active sectors. 36Kr has witnessed and accompanied the growth of innovative enterprises in this field and brought professional voices to the industry.
For this reason, 36Kr has launched the "Healthcare Industry Weekly Report" column, which will be released regularly to provide readers with industry information from multiple perspectives, including capital, policies, finance, and new products.
Please check the Healthcare Industry Weekly Report for November 17. This weekly report includes financing news in the healthcare field this week.
Financing and Investment
- "LemonBio" Secures Over 100 Million Yuan in Series A Financing
LemonBio has recently completed a Series A financing of over 100 million yuan. This round of financing is led by Fuhui Ventures, with Junyi Investment and XtalPi as co-investors. The raised funds will be mainly used for the IND application of the core CAR-T cell drug, the research and development of automated production processes, and the acceleration of the clinical transformation of metabolic-enhanced solid tumor cell therapy drugs. LemonBio was founded by the team of Professor Tang Li from the École Polytechnique Fédérale de Lausanne (EPFL) in collaboration with XtalPi, focusing on the research and development of innovative tumor immunotherapy drugs combining immune metabolic reprogramming (Meta 10) and AI.
- "Tianwu Technology" Completes Over 100 Million Yuan in Series A Financing
"Tianwu Technology" has recently completed a Series A financing of over 100 million yuan. This round of financing is led by Qiming Venture Partners, with Yonghua Investment, Jingtao Capital and the old shareholder Herbal Capital and other institutions as co-investors. The raised funds will be mainly used for the development of self-developed projects, as well as the technological iteration and upgrade of the general artificial intelligence for protein design AccelProtein™ (derived from the Pro series artificial intelligence developed by the Hongliang Team of Shanghai Jiao Tong University). Tianwu Technology was established in 2021, focusing on the use of AI for protein design and serving the fields of innovative drugs, in vitro diagnostics, nutrition and health care. The core members of the founding team come from Shanghai Jiao Tong University and have been deeply engaged in the field of AI proteins for many years.
- "Moyang Biotech" Completes Nearly 100 Million Yuan in Series B+ Financing
Moyang Biotech has completed the Series B+ financing with a financing amount of nearly 100 million yuan. This round of financing is jointly led by Boyuan Capital, SAIC Hengxu Capital and Yanbei Capital, with the continuous support of the old shareholder Jinding Capital. The raised funds will be mainly used for the establishment of sales, marketing, medical, brand teams, and the R&D investment in the next-generation products. Moyang Biotech was established in 2018, with modified hydroxyapatite material as the core, focusing on the development and industrialization of nano-medical biomaterials and absorbable Class III implant products. The company's founder, Lin Guangming, has been deeply engaged in the field of biomaterials for many years.
- IMPACT Pharmaceuticals Announces the Successful Completion of a 250 Million Yuan RMB Series D++ Financing
Nanjing IMPACT Pharmaceuticals Co., Ltd., an innovative drug research and development company focusing on the synthetic lethality mechanism of tumors, announced the recent successful completion of a 250 million yuan RMB Series D++ financing. This round of financing is jointly invested by a globally renowned industrial investment institution and a well-known insurance fund. Zhoudu Capital served as the exclusive financial advisor for this round of financing. This round of financing will support the commercialization of IMPACT's core product Senaparib, which has the best-in-class therapeutic effect, and the global clinical development of multiple compounds including the PARP1 selective inhibitor, as well as accelerate the R&D of multiple early-stage projects.
- Tongrui Bio Completes Over 100 Million US Dollars in Series A+ Financing
Tongrui Bio-Pharmaceutical (Chengdu) Co., Ltd., a radiopharmaceutical enterprise, announced the completion of a Series A+ financing of over 100 million US dollars. This round of financing is jointly led by the Shenzhen Capital Group Manufacturing Transformation and Upgrading New Materials Fund and Tailong Investment, with GL Ventures, 3SBio (01530.HK), Guanghua Wutong, and a certain well-known industrial investment institution and other well-known institutions and industrial parties jointly participating in the investment. Kaichen Capital served as the exclusive financial advisor for this transaction. The main purpose of this round of financing is to further improve the company's core technology platforms such as target precursor discovery, upgrade the high-throughput screening ability of innovative RDC drugs, accelerate the clinical development process of multiple internationally leading R&D pipelines, especially α-nuclide RDC drugs, and bring more effective treatment options to global patients.
The Frontline
- "Elekta" Doubles Down on Its Localization Strategy in China with the Debut of the Intelligent Adaptive Integrated Radiotherapy Platform | The Frontline
In the current medical market, radiotherapy is becoming an effective means to precisely target tumor tissues from a medical concept. Relevant data shows that nearly 70% of cancer patients need radiotherapy as a targeted treatment or adjuvant therapy, and the radical cure rate of radiotherapy for tumors can reach more than 40%, making it one of the internationally recognized mainstream treatment options.
Recently, at the 7th China International Import Expo (hereinafter referred to as the "CIIE"), the global precision radiotherapy enterprise "Elekta" debuted three innovative radiotherapy equipment and solutions, including the Elekta Evo Intelligent Adaptive Integrated Radiotherapy Platform.
In simple terms, adaptive radiotherapy is a new radiotherapy technology extended from image-guided radiotherapy, equivalent to turning the entire radiotherapy process, from positioning, plan design, plan experimentation to verification, into a dynamic closed-loop system that can self-respond and correct. Its purpose is to improve the accuracy and precision of treatment implementation, to achieve high-dose irradiation of the tumor target area while minimizing the possibility of high-dose irradiation to the surrounding normal tissues, thereby increasing the local tumor control rate while reducing the occurrence of radiation complications. In recent years, the concept of adaptive radiotherapy is gradually being accepted and popularized by domestic medical institutions.
It is understood that the Elekta Evo, which debuted in the Asian region this time, is to help clinicians flexibly deal with various different indications by "providing unlimited clinical freedom through a one-stop integrated solution", so as to provide personalized treatment for patients... (Click here for more details)
- In 2025, the Innovative Medical "Black Technology" Most Likely to Debut in China Is Here
The annual China International Import Expo (hereinafter referred to as the "CIIE") has come to a close.
In the medical device exhibition hall, which has attracted much attention over the years, more than 260 enterprises from around the world participated this year, and the world's top 10 medical enterprises and 11 Fortune 500 pharmaceutical companies all made their appearances. For these multinational medical enterprises, this has always been an "innovation weathervane", and many products that have not been officially approved have benefited from the spillover effect of the CIIE and accelerated the listing process in China.
Last year, we had reviewed the innovative medical products at the CIIE that targeted a wide range of indications and have already or are expected to become "blockbuster drugs". What are the new highlights at this year's CIIE?... (Click here for more details)
Editor: Hu Xiangyun